Celcuity (NASDAQ:CELC) Price Target Raised to $177.00

Celcuity (NASDAQ:CELC) had its target price hoisted by Citizens Jmp from $160.00 to $177.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Several other equities research analysts also recently commented on CELC. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Leerink Partners set a $155.00 price target on shares of Celcuity in a research report on Tuesday, June 2nd. Macquarie Infrastructure set a $160.00 price target on Celcuity in a research note on Thursday, May 28th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, HC Wainwright increased their price objective on Celcuity from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $155.18.

Celcuity Price Performance

Shares of CELC opened at $88.38 on Wednesday. Celcuity has a 12-month low of $13.47 and a 12-month high of $151.02. The business’s fifty day moving average is $108.17 and its 200 day moving average is $110.80. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a market cap of $4.31 billion, a P/E ratio of -22.66 and a beta of 0.16.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. Sell-side analysts anticipate that Celcuity will post -3.76 earnings per share for the current fiscal year.

Insider Buying and Selling at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.33% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Several hedge funds have recently modified their holdings of CELC. Handelsbanken Fonder AB purchased a new position in shares of Celcuity in the 2nd quarter worth approximately $1,099,000. Assenagon Asset Management S.A. purchased a new stake in shares of Celcuity during the second quarter valued at approximately $19,683,000. Parallel Advisors LLC bought a new stake in Celcuity during the first quarter worth $38,000. Janus Henderson Group PLC lifted its holdings in Celcuity by 54.8% during the first quarter. Janus Henderson Group PLC now owns 9,600 shares of the company’s stock worth $1,095,000 after acquiring an additional 3,400 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in Celcuity by 139.1% during the first quarter. EverSource Wealth Advisors LLC now owns 820 shares of the company’s stock worth $94,000 after acquiring an additional 477 shares during the period. Institutional investors own 63.33% of the company’s stock.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity won FDA approval for REVTORPYK in advanced HR+/HER2- breast cancer, a key catalyst that validates the drug and could support future revenue growth. Celcuity gains FDA approval for closely watched breast cancer drug
• Positive Sentiment: Several recent coverage items highlight optimism that the approval could position Celcuity as a more attractive oncology asset, even raising speculation it could draw interest from larger pharmaceutical companies. With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
• Neutral Sentiment: HC Wainwright kept a Buy rating and $155 price target, but trimmed earnings estimates for FY2026 and multiple 2027 periods, reflecting a more cautious near-term profit outlook despite the long-term story remaining intact.
• Negative Sentiment: Investor concern is building around commercialization timing and rollout execution, which has led some reports to say the FDA approval was not enough to offset questions about launch speed and market uptake. Celcuity Shares Down, FDA Approval Outweighed by Timeline Questions for Breast-Cancer Treatment
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Celcuity investors, adding a legal overhang that can pressure sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. – CELC

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.